No profile data available.
Xilio Therapeutics, Inc. (XLO) is a healthcare company in the additional cancer treatment drugs industry, based in Waltham, United States, with about 76 full-time employees.
It reported revenue of $43.77 million for fiscal year 2025, up 589.9% from fiscal year 2024, and net income of -$35.04 million. Its market capitalization was $59.55 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
Xilio Therapeutics reported $43.77 million in revenue for fiscal year 2025, up 589.9% from $6.34 million in fiscal year 2024.
$59.55 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include OS Therapies Incorporated (OSTX), Maia Biotechnology, Inc. (MAIA), Oncolytics Biotech Inc. (ONCY), Boundless Bio, Inc. (BOLD).